Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

David A. Bond, Ying Huang, John C. Reneau, Yazeed Sawalha, Jonathan E. Brammer, Timothy Voorhees, Narendranath Epperla, Audrey M. Sigmund, Lapo Alinari, Walter Hanel, Anna Gilmore, Misty Fleming, Kathleen Stamper, Robert Baiocchi, Beth Christian, Kami J. Maddocks

Blood (2024) 144 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2024-194545

Published: 2024

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2024-203798

Published: 2024

Journal Articles

Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas

John C. Reneau, Ying Huang, Walter Hanel, Jonathan E. Brammer, Catherine Chung, Basem William

Blood (2024) 144 (Supplement 1): 4438.

https://doi.org/10.1182/blood-2024-201294

Published: 2024

Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Blood (2024) 144 (Supplement 1): 4433.

https://doi.org/10.1182/blood-2024-210301

Published: 2024

Journal Articles

Final Results of a Phase 2, Single Arm Trial Evaluating Letermovir for Cytomegalovirus Prophylaxis in Patients with Hematological Malignancies Treated with Alemtuzumab

John C. Reneau, Ying Huang, Walter Hanel, Catherine Chung, Jonathan E. Brammer, Basem William

Blood (2024) 144 (Supplement 1): 6390.

https://doi.org/10.1182/blood-2024-201307

Published: 2024

Journal Articles

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Sonia Godbole, Rina Li Welkie, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C. Reneau, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2024) 144 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2024-207738

Published: 2024

Journal Articles

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Xiangrong Geng, Chenguang Wang, Thilini Perera, Badeia Saed, Ying Hu, Ashley Wolfe, John C Reneau, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2023-172509

Published: 2023

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Allison M Lehanka, Ann Kebede, Neda Amirmokhtari, Joseph R Stanek, Narendranath Epperla, Beth Christian, Robert Baiocchi, Timothy Voorhees, Kami J. Maddocks, Yazeed Sawalha, John C Reneau, Jonathan E. Brammer, Audrey M. Sigmund, Faye Willen, Nick Yeager, Anthony N. Audino, David A. Bond

Blood (2023) 142 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2023-187194

Published: 2023

Journal Articles

Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas

Zachary Braunstein, Allyson Waller, Emily Dotson, Eric McLaughlin, Walter Hanel, John C Reneau, Daniel Addison, Pierluigi Porcu, Jonathan E. Brammer

Blood (2023) 142 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2023-184583

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Narendranath Epperla, Xinyu Wang, Hong Li, David A. Bond, Yazeed Sawalha, John C. Reneau, Timothy J. Voorhees, Kami J. Maddocks, Beth Christian, Walter Hanel, Lapo Alinari, Lalit Sehgal, Robert A. Baiocchi, James L. Lee

Blood (2022) 140 (Supplement 1): 11873–11875.

https://doi.org/10.1182/blood-2022-164907

Published: 2022

Journal Articles

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

Zachary Braunstein, Miguel Ruiz, Eric McLaughlin, Naresh Bumma, Don M Benson, Jr., Srinivas Devarakonda, Maria Chaudhry, Abdullah Khan, Francesca Cottini, John C. Reneau, Pierluigi Porcu, Anjali Mishra, Ashley E. Rosko, Jonathan E Brammer

Blood (2021) 138 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2021-152556

Published: 2021

Journal Articles

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Basem M. William, John C. Reneau, Amanda Campbell, Anna Vilgelm, Michelle Watts, Lynn O'Donnell, Ying Huang, Catherine Chung, Marcos J.G. de Lima, Steven Devine, Sumithira Vasu, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2021-150543

Published: 2021

Journal Articles

Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study

Megan Fleming, Ying Huang, Emily Dotson, David A. Bond, John C. Reneau, Narendranath Epperla, Jonathan E. Brammer, Beth Christian, Lapo Alinari, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2021) 138 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2021-148662

Published: 2021

Journal Articles

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

Walter Hanel, MD, Beth A. Christian, MD, Kami J. Maddocks, MD, Narendranath Epperla, MDMS, Basem M. William, MDMRCP, Samantha Jaglowski, MD MPH, David A. Bond, MD, Yazeed Sawalha, MD, John C. Reneau, MDPhD, Jonathan E Brammer, MD, Robert Baiocchi, MD PhD, Kristie A. Blum, MD, Lapo Alinari, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-141243

Published: 2020

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

John C. Reneau, MD, Steven R. Hwang, MD, Carlos A. Murga-Zamalloa, MD, Joseph J. Buggy, PhD, James W. Janc, PhD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2018-99-110554

Published: 2018

NARROW

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Final Results of a Phase 2, Single Arm Trial Evaluating Letermovir for Cytomegalovirus Prophylaxis in Patients with Hematological Malignancies Treated with Alemtuzumab

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only